MESOBLAST LIMITED ORDINARY (MSB) Short Interest
MESOBLAST LIMITED ORDINARY (ASX:MSB) had 8.29% of shares reported as short positions as of 25 June 2026, representing 107,345,740 shares. MESOBLAST LIMITED ORDINARY operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
MSB
Mesoblast
Mesoblast is a leader in the development of innovative cellular medicines based on its proprietary mesenchymal lineage adult stem cell technology. The company focuses on developing treatments for inflammatory diseases, cardiovascular diseases, and orthopedic conditions. Mesoblast's unique value lies in its extensive intellectual property portfolio and its ability to manufacture allogeneic cellular...